ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Pulmonary Neuroendocrine (Carcinoid) Tumors: European Neuroendocrine Tumor Society Expert Consensus and Recommendations for Best Practice for Typical and Atypical Pulmonary Carcinoid

Tuesday, February 3, 2015

Submitted by

Mark Ferguson

Source

Source Name: Annals of Oncology

Source URL: http://annonc.oxfordjournals.org/content/early/2015/02/02/annonc.mdv041.abstract…

Author(s)

M.E. Caplin, E. Baudin, P. Ferolla, P. Filosso, M. Garcia-Yuste, E. Lim, K. Oberg, G. Pelosi, A. Perren, R. Elisa Rossi, W.D. Travis, the ENETS consensus conference participants

This consensus statement from the European Neuroendocrine Society is based on extensive bibliographic searches and systematic review. Surgery is the mainstay of therapy for most tumors, and includes resection of metastases when this can be accomplished in a curative manner. Somatostatin analogues are considered first line therapy for unresectable carcinoids, whereas systemic chemotherapy is most appropriate for progression of disease.